). Anxiety, EDS, and QoL showed similar improvement in pre-post-test analysis, but a lack of superiority to dental appliances and sham PAP. PAP was superior to all comparators for respiratory variables. PAP has a moderate clinical effect on symptoms of depression and anxiety in OSA, but it is not superior to dental appliances or sham PAP. The improvement in subjective symptoms, such as depression and anxiety, may be mediated by patient expectations and contact with healthcare providers.
Introduction
Obstructive sleep apnea (OSA) is characterized by repetitive sleep-related episodes of complete (apnea) or partial (hypopnea) obstruction of the upper airway or respiratory effort related arousals (RERAs) [1, 2] . Globally, OSA associated with daytime sleepiness is reported to occur in 2%e5% of adult women and 3%e7% of adult men [1, 2] . OSA is associated with multiple other medical comorbidities including; hypertension, insulin-resistance, type II diabetes, and obesity [2] . Positive airway pressure (PAP) delivered in continuous (CPAP), bilevel (BiPAP) or autotitrating (APAP) modes is a standard therapy for moderate (respiratory disturbance index (RDI) !15 and 30) to severe (RDI>30/hour) OSA and an optional therapy for mild (RDI!5 and <15) OSA [3, 4] . PAP is believed to be effective in reducing the apnea-hypopnea index (AHI) or RDI by providing pneumatic splinting of the upper airway during sleep [3, 5] . There is a large body of evidence showing that PAP improves objective symptoms of OSA including the AHI and blood pressure [6] .
The presence of psychological symptoms in patients with OSA has been recognized since the 1970s [7] and significant evidence that there are elevated levels of OSA in patients with clinical depression has emerged since the early 2000s [8] . The recognition of the importance of depression in OSA is exemplified by the fact that in the most recent edition of the International classification of sleep disorders [ICSD3], diagnosis of a mood disorder (Criterion A.4) is among one of the four major groups of symptoms (eg., excessive daytime sleepiness, habitual snoring) or disorders (eg., hypertension, atrial fibrillation) that must be present along with !5 obstructive respiratory events per hour, before an OSA diagnosis can be made.
The relationship between objectively-rated features of OSA and symptoms like depression, anxiety, and excessive daytime sleepiness (EDS) is poorly understood [8e10] . This constellation of symptoms is often referred to as subjective symptoms of OSA, as there is typically no consistent correlation between the severity of these symptoms and the severity of OSA measured by objectively-rated sleep variables [11e17] . Current models for the relationship between OSA and psychiatric conditions suggest that underlying biological, metabolic and neurological dysregulation contributes to a feed-forward mechanism that manifests as psychiatric disorders, sleep fragmentation, cardiovascular and metabolic disease [8e10] . Given that the subjective symptoms of OSA are the result of complex biological dysregulation, it remains unclear whether these symptoms have a direct response to PAP therapy. Saunamaki et al. found that symptoms of depression and anxiety were commonly reported in treatment naïve OSA patients with multiple studies reporting improvements in these symptoms after !3 mo of PAP [11] . Sanchez et al. also reported on improvements in symptoms of EDS and mood in response to CPAP therapy [18] . Both of these reviews reached their conclusions by focusing on the number of studies reporting the positive effects of PAP; this type of analysis is less accurate as it presents the overall research in the field by study outcome, whereas meta-analysis pools participant data across studies to create a more accurate analysis of the effects of PAP based on the total population studied [11, 18] . A recent meta-analysis concluded that treatment of OSA with PAP or mandibular advancement devices is superior to placebo for the treatment of depressive symptoms, but did not evaluate PAP vs. active therapies [19] . The goal of this systematic review and metaanalysis is to determine if PAP therapy improves depression and other subjective symptoms in OSA in comparison to both placebo and active treatments, as measured by validated rating scales.
Objective
The primary objective is to determine if treatment with PAP improves the psychological symptoms of depression in patients with OSA. The secondary objective was to evaluate if PAP improved additional subjective sleep outcomes including: anxiety and EDS.
Methods
The methodology for this paper follows PROSPERO protocol CRD42014007419 registered February 3, 2014 in accordance with the preferred reporting items for systematic reviews and metaanalyses (PRISMA) statement [20, 21] .
Eligibility criteria

Types of studies
This review considered single arm trials (SAT), case-control trials, and randomized controlled trials (RCTs) of both parallelgroup and crossover design of PAP interventions for OSA.
Types of participants
Adult men and women with OSA diagnosed by polysomnography (PSG) were included. OSA was defined as an AHI !5 (or RDI equivalent). Studies were only included when participants were treatment naïve at study initiation. Studies where the primary study sample involved individuals with severe or acute co-morbid medical illness such as acute myocardial infarction, stroke, dementia or heart failure were also excluded.
Types of interventions
Studies included PAP devices titrated to an effective pressure to overcome the respiratory disturbance. The analyses include studies with comparators consisting of healthy controls, sham or placebo PAP groups or active comparator controlled studies. This analysis also considered participant controlled pre-and post-intervention data.
Types of outcome measures
The primary outcome measure for the meta-analysis was depression. On this basis, all studies were required to include at least one validated measure of depression such as the Beck depression inventory (BDI), Montgomery-Asberg depression rating scale (MADRS), hospital anxiety and depression scale (HADS), or Hamilton depression scale (HAM-D). Secondary outcome measures included anxiety, EDS, and quality of life (QoL). This meta-analysis also evaluated the polysomnographic (PSG) indices: AHI/RDI, mean oxygen saturation (Mean SaO 2 ), minimum oxygen saturation (Min SaO 2 ), and arousal index (AI). These outcomes were included as they have known physiological efficacy in OSA. As known objective outcome measures, they can provide context for the subjective measures evaluated.
Abbreviations
Additional outcome measures present in the studies were included if they were identified during data extraction.
Information sources
Electronic searches
The 
Search
The search strategies for all databases are included in Supplement 1. The reference lists of all primary studies and review articles were checked for additional references.
Study selection
Studies were screened for relevance to the topic by title, followed by abstract and/or full text article. Articles were screened for inclusion by two reviewers (FS and DL). Studies that were not in English or conducted using animals were excluded.
Data collection process
Data extraction was performed by two independent reviewers (FS and DL) using data collection forms. The data forms were piloted before use and included: Study identifier, study design, number of participants per group, baseline characteristics, intervention, treatment regimen and duration, treatment success and failure, efficacy, safety, morbidity and mortality, tolerability, compliance, number of patients lost to follow-up, and the duration of follow-up. Disagreements were resolved with discussion, or if agreement could not be reached, a third author (MAG) assisted in the resolution of any discrepancies. The data were entered by a single author (FS) and verified by both reviewers (FS and DL). Data were entered as intention-to-treat (ITT) data, and per protocol results was converted into ITT data wherever possible to reduce bias.
Risk of bias in individual studies
The risk of bias (RoB) in individual studies was evaluated using the Cochrane risk of bias tool in RevMan version 5.2 (Copenhagen, Denmark) [22, 23] .
Measures of treatment effect
Treatment effect was assessed by meta-analysis if there were !2 studies that assessed the outcome measure. Effect size was presented using Hedges' g for continuous measures and odds ratios (OR) for binary data [22, 24] . If there was insufficient evidence for meta-analysis, the study outcomes were described verbally, and not included in the meta-analysis.
Unit of analysis issues
The unit of analysis reported was the participant. In cross-over study designs, participant controlled data were used wherever possible or the first intervention period was used where participant-controlled data were unavailable. If studies reported more than one outcome measure included in this review, all of the outcomes were included in the analyses.
Dealing with missing data
Principal investigators and/or study sponsors were contacted to obtain missing data and verify any unclear study parameters. Where this was not possible, and the missing data was felt to introduce a serious bias, sensitivity analysis was conducted to explore the impact of the missing data.
Assessment of heterogeneity
The I 2 statistic was used to measure the proportion of variance attributable to heterogeneity among the trials in each analysis [22, 24] . Where substantial heterogeneity was identified, it was reported and possible causes were explored by pre-specified subgroup analysis. Heterogeneity was stratified into I 2 values for low (25%), medium (50%) and high (>75%) heterogeneity [24] .
Assessment of reporting biases
Analyses containing !10 studies were assessed for publication bias using funnel plots and Duval and Tweedie's trim and fill method [24] .
Data synthesis
All meta-analyses were conducted with a pre-specified randomeffects model to account for heterogeneous treatment effects and varying true effect sizes across studies. Meta-analyses were required to have an I 2 value 75% for inclusion. Where more than one scale was used to assess an outcome measure (i.e., depression by BDI and HADS), the mean of the outcomes was used. Pre-post test analysis used the PAP arm of SATs, parallel RCTs, and crossover RCTs where pre-and post-test data were presented. The analyses for RCTs used both parallel and crossover designs, where the crossover trials presented participant controlled data. The metaanalysis calculations were performed using Comprehensive MetaAnalysis Version 2.2.064 (Englewood, NJ) [25] .
Risk of bias across studies
The RoB across studies was evaluated for each meta-analysis using grades of recommendation, assessment, development and evaluation (GRADE) and GRADEpro software [22, 26] .
Subgroup analysis and meta-regression
Prospective subgroup and meta-regression analysis were intended to be conducted by gender, OSA severity (AHI/RDI), body mass index (BMI), arousal index (AI), and baseline depression severity based on the heterogeneity of the results. However, as all of the pre-specified analyses had heterogeneity below 50%, these analyses were not included in the final manuscript.
Results
Description of studies
Results of search
The results of the search strategy can be found in Fig. 1 . The search was completed on June 20, 2014. Thirty-three reports of 31 studies met the inclusion criteria for this review (Supplement ,  Table S2 ) [27e59].
Included Studies
A list of the included studies can be found in Table S2 . The characteristics of the included studies are summarized in Table 1 .
Study design
The included studies are comprised of single assignment trials, randomized trials, and current or future study protocols (Table 1) . Fig. 1 shows the number of each class of trial identified. Of the randomized studies, four were parallel assignment studies [42, 45, 46, 52, 59 ] and six were crossover trials [28,37e40,47] .
Participants
The included studies enrolled a total of 895 participants. Seven studies enrolled fewer than 20 participants [33, 34, 39, 48, 50, 52, 58] , and two studies enrolled more than 100 participants [28, 44] . Participant mean BMI ranged from 27.8 to 38 kg/m 2 where recorded, indicating that the participants ranged from overweight to obese [34, 52, 58] . Participant mean baseline AHI ranged from 11.0 to 71.5 per hour where reported, including a full spectrum of mild to severe OSA [39, 48] .
Interventions
A total of seven interventions were measured in the included studies. All of the studies evaluated CPAP devices. In addition to the required PAP treatment, the completed studies included oral placebo [28,37e40] , oral/dental appliances [28, 52] , exercise [52] , and sham PAP [42,45e47,59] . Two trial protocols also included gastric bypass surgery and lifestyle/behavioural modification as arms of parallel-assignment trials [30, 31] . The studies ranged in duration from 11 d to two y [57, 59] .
Outcomes
The included studies reported a diverse array of psychological and physiological outcome measures ( In cases where there were multiple records of a study population, they were combined under a single study identifier to prevent duplication. 
Excluded studies
There were 46 studies excluded from the full text search (Table S3 ). The primary reason for exclusion was an inability to extract data from studies that otherwise met the inclusion criteria, when contacting the authors failed (Table S4 ). The secondary reasons were lack of a psychiatric scale and OSA diagnoses reported without PSG results (Table S4) .
Risk of bias in included studies
Allocation
The studies identified in this systematic review were primarily single-assignment prospective trials or retrospective reviews. Of the 10 completed randomized controlled studies, two had adequate randomization procedures (Fig. 2) [37, 45] . Allocation concealment was only possible in the four sham controlled PAP studies. The method of concealment was not described in three of these studies [42, 45, 59 ] and in the fourth study participants were informed that the trial was for two different pressures of humidified PAP [47] .
Blinding
The blinding of studies in this systematic review was subject to either unclear or high risk of bias (Fig. 2) . The single-assignment trials largely do not discuss blinding and are presumably open label trials. Of the 10 randomized controlled trials, five are crossover studies of mixed treatments which cannot be participant-blinded [28,37e40] , one is a crossover of PAP and sham PAP which does not report blinding [47] , and two of these are open-label trials without evaluator blinding [38, 40] . Of the five parallel group studies, two had adequate blinding of participants and evaluators [45e47], while the other three had unclear blinding procedures [42, 52, 59 ].
Incomplete outcome data
Incomplete outcome data were absent in the majority of completed studies (Fig. 2) . There was a low risk of bias for incomplete outcome data in 20 studies. Unclear outcome data were present in two studies [29, 49] . There was a high risk of bias for incomplete outcome data in three studies [44, 54, 59 ].
Effect of interventions
The magnitude of change caused by the interventions is presented as effect size measured as Hedge's g. The interpretation of these effect sizes requires context to determine how the statistical effect size corresponds to the magnitude of clinical change observed. Based on the range of effect sizes presented in this analysis and their correlations to known objective measures of the effects of PAP on sleep symptoms such as AHI [6] , effect sizes will be interpreted as <0.5 low, 0.5e1.0 moderate and >1.0 as high.
PAP pre-post intervention
Twenty-one of the included studies assessed the change in depression and other outcome measures pre-and post-PAP treatment (Table 3) (Table 3) . These analyses are subject to an overall high RoB with a GRADE evaluation of 'very low' for all outcome measures other than AHI/RDI which was 'low'. The effect size for the primary outcome measure of depressive symptoms was 0.524 [0.401e0.647], which corresponds to a moderate clinical effect (Fig. 3A) . A high effect size was observed for symptoms of EDS (1.015 [0.697e1.333]) (Fig. 3C) Figure S1B ) also showed moderate effect sizes, but the 95% CI indicates that these are not clinically significant.
PAP versus oral placebo
Comparisons of PAP with oral placebo were conducted in five of the included studies (Table 4 , Fig. 4) [28,37e40] . All of the analyses indicate that PAP is more effective than oral placebo (Table 4 , Fig. 4 and S2). These analyses are subject to an overall high RoB with a GRADE evaluation of 'low' for all outcome measures other than EDS which was 'moderate'. The primary outcome measure for depression showed a low effect size of 0.355 [0.187e0.524] (Fig. 4A) . The change in EDS was moderate with an effect size of 0.608 [0.090e1.126] (Fig. 4C) The meta-analysis for QoL had moderate heterogeneity of 33.96% which is larger than the heterogeneity observed for the other analyses in this comparison. The moderate QoL heterogeneity between the included studies may be due to the number of varying QoL scales that were utilized.
PAP versus dental appliances
Two studies compared PAP and dental appliances (Table 5 Fig. 5D ). There was a low effect size favoring PAP for anxiety 0.101 [0.078e0.280] (Fig. 5B) . The effect size for AHI/RDI favored PAP over dental appliances with a moderate effect size of 0.902 [0.692e1.113] ( Figure S2A ). There was also a low effect size of 0.473 [0.285e0.661] favoring PAP for improvements in AI ( Figure S2B ).
PAP versus sham PAP
Four studies compared PAP to sham PAP (Table 6 , Fig. 6 and S4) [42,45e47,59 ]. The analyses for depression, anxiety and mean SaO 2 received 'low' GRADE assessment scores, while the AHI/RDI analysis received a 'high' GRADE assessment. (Figure S3B ), but the large 95% CI indicates that this result has too much variance to be considered clinically relevant. EDS and QoL were not assessed in the PAP vs. sham PAP studies.
PAP vs. exercise
One study evaluated PAP vs. exercise for the treatment of OSA [52] . Meta-analysis was not possible; however, this study did measure the difference in depression, EDS, anxiety, QoL and AHI. All of the effect sizes favored PAP over exercise. Depression and anxiety were measured using the profile of mood states (POMS) scale. The effect size for POMS-depression was low at 0.094 ± 0.477 (Hedge's g ± SE) and the effect size for POMS-tension and anxiety was also low at 0.349 ± 0.480. EDS was measured by the Epworth sleepiness scale (ESS) with a moderate effect size of 0.709 ± 0.493. The effect sizes for respiratory variables were both large with 2.007 ± 0.594 for AHI and 1.033 ± 0.510 for AI. The effect size for the SF-36 mean score was also large at 1.225 ± 0.523.
Discussion
Summary of main results
Our systematic review identified 31 studies pertaining to the effects of PAP on depressive symptoms in individuals with OSA. Of the included studies, 26 were completed trials and five were trial protocols that are currently active or enrolling participants. The majority of studies were single-assignment prospective trials or retrospective reviews. The results of this meta-analysis show that PAP had a moderate impact on symptoms of depression and anxiety when the psychological measures were carried out pre-to post-PAP. PAP had low impact on symptoms of depression and anxiety when compared with oral placebo, but was not more effective at reducing depression and anxiety than sham PAP or dental appliances. In contrast, PAP was consistently more effective than placebo, sham PAP or dental appliances in decreasing the AHI.
This review confirms that the relationship between depression, anxiety, EDS and OSA is complex. The contrast between subjective and objective symptoms is underscored by the fact that PAP is consistently more effective than placebo and active treatment comparisons at improving all respiratory variables; including AHI/ RDI, AI, and mean SaO 2 . It has previously been hypothesized that OSA, psychological symptoms, and metabolic disease are the diverse consequences of underlying biological, metabolic and neurologic dysregulation [8e10]. Psychiatric, sleep and metabolic disorders can each be the primary manifestation and entry point into a feed-forward mechanism where underlying inflammation, oxidative and nitrosative stress, and neurotransmitter imbalances increase the likelihood of the individual expressing multiple disease states related to the underlying biological dysregulation [8] . In some individuals, the development of OSA and resultant sleep fragmentation may unmask an underlying predisposition for depressive disorders. The application of PAP is unlikely to resolve these problems directly, as PAP can only directly treat the respiratory symptoms that are an outcome of a complex process. Improvement in AHI that is dependant solely on PAP, without other autonomic and metabolic changes, may not be sufficient to be associated with a clinically significant improvement in depression, anxiety and EDS scores. The improvements in these symptoms may derive from decreased arousals and hypoxemia or the long-term positive impact of PAP on metabolic function [60, 61] . Alternatively, the improvement in depressive symptoms in pre-post-test analysis and in comparison to oral placebo may be the result of patient expectations, mediated primarily by interaction with the healthcare system and reassurances of improvement in the participant's condition [62] . Many of the included studies occur over prolonged durations >90 d, where this interaction may have a significant impact.
Overall completeness and applicability of evidence
The evidence for the efficacy of OSA in alleviating symptoms of depression is largely incomplete. The duration of the studies ranged from 11 d to 2 y (Table 1) and this is likely an important confounding factor in the improvement of a complex syndrome like depression after treatment of the respiratory component of OSA with PAP therapy. The lack of significant heterogeneity in the analyses suggests that time was not a significant factor in these analyses. One possible reason for the lack of an impact is that PAP is predominantly a symptomatic treatment that is only effective when being used, so the length of treatment is not a significant factor, despite known improvements in cardiovascular and endocrine function with PAP [6, 60, 61] .
A second concern is the lack of RCTs assessing the effects of PAP in comparison to dental appliances, sham PAP and exercise. While there is an abundance of low quality evidence for the effect of PAP pre-and post-treatment, there is insufficient evidence for the assessment of the outcomes of PAP vs. placebo and active comparators. The highest volume of data exists for the comparison of PAP vs. oral placebo, but this is likely the least convincing placebo arm for participants, despite instructions to the contrary. The evidence for comparing PAP to dental appliances for psychological symptoms is sparse, as is the evidence for PAP vs. sham PAP which is the gold standard control.
An additional problem with the completeness of this evidence is the lack of dichotomous outcomes for clinical depression and anxiety. This meta-analysis exclusively uses continuous outcome measures of varying levels of psychological symptom severity. The combination of multiple scales measuring the same psychometric properties, but on different numerical scales, prevents us from conducting meta-regression to determine if baseline severity has an effect on the magnitude of change in depression. It would be valuable to have data organized to give the proportion of participants meeting the severity criteria for clinical depression before and after PAP to see if these proportions change. It would also be valuable to be able to perform subgroup analysis on continuous outcomes within participants grouped by severity.
Quality of the evidence
The quality of the evidence included in this review and metaanalysis is low overall, reflecting the fact that the bulk of the data was published before the widespread adoption of the consolidated standards of reporting trials (CONSORT) statement, which is based on the two-group parallel design [63] . The GRADE assessments for the meta-analyses performed in this review were predominantly 'very low'. The decision to evaluate single-arm trials of PAP was based largely on the lack of availability of randomized controlled trials; however, the quality of the evidence based upon single-arm trials should be taken into consideration when interpreting the clinical efficacy indicated by the results. It is particularly telling that the effect size for the primary outcome measure of depression diminishes as the methodological quality of the RCTs comparator arm improves. This effect can be underscored by the fact that the effect size for depression is null À0.049 [À0.292e0.194] when PAP is compared to sham PAP, but the effect size for change in AHI/RDI for this comparison is the largest effect size 1.881 [1.370e2.391] reported in the analysis.
Limitations
This meta-analysis includes single-assignment and randomized clinical trials with both parallel group and cross-over designs, but there are more SATs than RCTs present in the analysis. A similar meta-analysis published assessing mandibular advancement devices or PAP in comparison to placebo focused solely on RCTs [19] . There are advantages to pre-post PAP analysis, but the low RoB associated with SATs cannot be overlooked. The other limitation of this meta-analysis is the use of multiple scales to measure the same psychometric variable [19] . The use of Hedge's g should help to account for variability in the scale ranges, but this is predicated on each scale having equivalent ability to measure the same underlying construct, which may not be true in all cases. The ratings of depression were primarily participant-rated and AHI e apnea hypopnea index, AI -arousal index, EDS -excessive daytime sleepiness, FOSQ -functional outcomes of sleep questionnaire, GRADE -grades of recommendation, assessment, development and evaluation, mean SaO 2 e mean oxygen saturation, QoL e quality of life, RDI -respiratory disturbance index. AHI e apnea hypopnea index, AI -arousal index, EDS e excessive daytime sleepiness, GRADE -grades of recommendation, assessment, development and evaluation, QoL e quality of life, RDI -respiratory disturbance index. Fig. 4 . PAP vs. oral placebo Forest plots. A) Depression, B) Anxiety, C) EDS, D) QoL. EDS e excessive daytime sleepiness, ESS e Epworth sleepiness scale, HADS-A e hospital anxiety and depression scale e anxiety subscale, HADS-D e hospital anxiety and depression scale e depression subscale, OP e oral placebo, PAP e positive airway pressure, POMS-T e profile of mood states -tension and anxiety subscale, QoL e quality of life, SF-36 -short form health survey (all subscales). AHI e apnea hypopnea index, AI -arousal index, FOSQ e functional outcomes of sleep questionnaire, EDS e excessive daytime sleepiness, GRADE -grades of recommendation, assessment, development and evaluation, QoL e quality of life, RDI -respiratory disturbance index. Fig. 5 . PAP vs. dental appliances Forest plots. A) Depression, B) Anxiety, C) EDS, D) QoL. DA e dental appliance, EDS e excessive daytime sleepiness, ESS e Epworth sleepiness scale, PAP e positive airway pressure, POMS-D e profile of mood states e depression subscale, POMS-T e profile of mood states -tension and anxiety subscale, QoL e quality of life, SF-36 -short form health survey (all subscales).
therefore subject to different types of biases than the measurement of AHI by PSG. The decision to only include validated psychometric scales in this analysis, without commonly accepted substitutes such as the SF-36 mental health subscale, should hopefully also help to combat this issue. This meta-analysis was also conducted using individual comparisons between each placebo and active comparator control and PAP. This means that oral placebo and sham PAP were assessed independently, rather than as pooled placebo groups, where another meta-analysis has distinguished between parallel and cross-over study methodology [19] . The participants in the oral placebo trials were participants in crossover trials where the distinction between PAP and the oral treatment received would be apparent to the participants, whereas the participants in the sham PAP trials were more effectively blinded to the trial arms. This meta-analysis was also unable to assess the impact of severe baseline depression versus subclinical depression. The studies used by Povitz et al. to assess severe baseline depressive symptoms were excluded from our analysis as one used the SF-36 mental health subscale and the other was conducted in stroke patients [19] . It would have been advantageous to compare the effect in severe and mild depression, as these populations are likely to have different subjective responses to PAP.
Conclusions
The effect of PAP on symptoms of depression and anxiety, EDS and QoL in patients with OSA was moderate. PAP was superior to oral placebo, but not to sham PAP in RCTs for depression and anxiety. PAP was also equivalent to dental appliances as a therapeutic option for improving subjective symptoms of depression and anxiety. PAP had a significant effect on the improvement of EDS which moderately favored PAP over oral placebo, but was equivalent to dental appliances. PAP was superior to all comparators for improvement in AHI, AI, and mean SaO 2 . The relationship between improvement in subjective symptoms of OSA and PAP is complicated by the low overall quality of the evidence. Future randomized controlled trials between PAP and sham devices or dental appliances will be needed to determine if the effects of PAP are specific to improvements in respiratory variables, or subjective improvements due to the placebo effect of interaction with healthcare providers. AHI e apnea hypopnea index, AI -arousal index, EDS -excessive daytime sleepiness, FOSQ -functional outcomes of sleep questionnaire, GRADE -grades of recommendation, assessment, development and evaluation, mean SaO 2 e mean oxygen saturation, QoL e quality of life, RDI -respiratory disturbance index. Practice points PAP improves depressive symptoms in patients with OSA, but it is not superior to dental appliances or sham PAP.
The beneficial effect of PAP may be greater in patients with higher depression severity scores. If symptoms of depression do not improve after PAP therapy with improvement of AHI, the depressive symptoms will need to be treated using standard psychiatric therapies while the patient's OSA symptoms are being monitored.
Research agenda
Randomized controlled trials should be conducted comparing the efficacy of PAP and sham PAP or active therapy in participants with clinical depression versus patients with subthreshold severity scores to determine the relative efficacy of PAP in these populations. Outcome measures such as depression, anxiety, EDS and quality of life should be included in all future trials of PAP in comparison to active and sham control arms for OSA. Study of the correlation between baseline AHI and response of subjective symptoms of depression and anxiety to PAP may help to clarify the link between disease severity and subjective patient outcomes. Future RCTs should consider evaluating treatment by time effects to determine the significance of length of treatment in the improvement in subjective symptoms of OSA such as depression.
* The most important references are denoted by an asterisk.
